Olof Akre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4191445/publications.pdf

Version: 2024-02-01

80 papers 3,268 citations

30 h-index 55 g-index

86 all docs 86 docs citations

86 times ranked 3877 citing authors

#	Article	IF	CITATIONS
1	Systematic review and meta-analysis: relationships between attention-deficit/hyperactivity disorder and urinary symptoms in children. European Child and Adolescent Psychiatry, 2022, 31, 663-670.	4.7	10
2	The 90â€day causeâ€specific mortality after radical prostatectomy: a nationwide populationâ€based study. BJU International, 2022, 129, 318-324.	2.5	1
3	Mortality in men with castrationâ€resistant prostate cancerâ€"A longâ€term followâ€up of a populationâ€based realâ€world cohort. BJUI Compass, 2022, 3, 173-183.	1.3	12
4	Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade. Clinical Epidemiology, 2022, Volume 14, 59-70.	3.0	2
5	Lymph swelling after radical prostatectomy and pelvic lymph node dissection. BJU International, 2022, 129, 695-698.	2.5	1
6	Association of Open vs Robot-Assisted Radical Cystectomy With Mortality and Perioperative Outcomes Among Patients With Bladder Cancer in Sweden. JAMA Network Open, 2022, 5, e228959.	5.9	15
7	Characteristics of Patients in SPCG-15—A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer. European Urology Open Science, 2022, 41, 63-73.	0.4	3
8	Oncologic outcomes of patients with incidental prostate cancer who underwent RARC: a comparison between nerve sparing and non-nerve sparing approach. Journal of Robotic Surgery, 2021, 15, 105-114.	1.8	4
9	Development and validation of nonâ€guided bladderâ€neck and neurovascularâ€bundle dissection modules of the RobotiXâ€Mentor® fullâ€procedure roboticâ€assisted radical prostatectomy virtual reality simulation. International Journal of Medical Robotics and Computer Assisted Surgery, 2021, 17, e2195.	2.3	10
10	Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer. Scientific Reports, 2021, 11, 3257.	3.3	11
11	COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials, 2021, 22, 209.	1.6	8
12	Urinary continence recovery and oncological outcomes after surgery for prostate cancer analysed by risk category: results from the LAParoscopic prostatectomy robot and open trial. World Journal of Urology, 2021, 39, 3239-3249.	2.2	11
13	Real world treatment utilization patterns in patients with castration-resistant prostate cancer. Scandinavian Journal of Urology, 2021, 55, 299-306.	1.0	4
14	Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer. Scientific Reports, 2021, 11, 13486.	3.3	3
15	Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulatorâ€mandated cohort postauthorization safety study in Denmark, Norway, and Sweden. Cancer, 2021, 127, 4050-4058.	4.1	13
16	Systematic review and metaâ€analysis identify significant relationships between clinical anxiety and lower urinary tract symptoms. Brain and Behavior, 2021, 11, e2268.	2.2	12
17	Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. European Urology, 2021, 80, 650-660.	1.9	46
18	Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiong's Letter to the Editor re: Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650–60. European Urology, 2021, 81, e43-e43.	1.9	0

#	Article	IF	Citations
19	Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study. European Urology, 2020, 77, 180-188.	1.9	87
20	Sex Differences in Urothelial Bladder Cancer Survival. Clinical Genitourinary Cancer, 2020, 18, 26-34.e6.	1.9	42
21	Risk of Recurrent Disease 6 Years After Open or Robotic-assisted Radical Prostatectomy in the Prospective Controlled Trial LAPPRO. European Urology Open Science, 2020, 20, 54-61.	0.4	7
22	Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. Scandinavian Journal of Urology, 2020, 54, 115-121.	1.0	36
23	Risk of Postoperative Up Staging or Upgrading among Men with Low Risk Familial Prostate Cancer. Journal of Urology, 2020, 204, 79-81.	0.4	4
24	DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer. Clinical Epigenetics, 2019, 11, 152.	4.1	7
25	Solid Science for the Upside but Lack of Solid Science for the Downside—Towards Cutting-edge Prostate-cancer Screening. European Urology, 2019, 76, 52-53.	1.9	2
26	Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study. American Journal of Epidemiology, 2019, 188, 1165-1173.	3.4	4
27	Preoperative staging using magnetic resonance imaging and risk of positive surgical margins after prostate-cancer surgery. Prostate Cancer and Prostatic Diseases, 2019, 22, 391-398.	3.9	28
28	Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer—A Systematic Literature Review and Pooling of Individual Participant Data. European Urology Focus, 2019, 5, 788-798.	3.1	5
29	Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 57-63.	3.9	134
30	Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up. European Urology Focus, 2018, 4, 351-359.	3.1	32
31	Nationwide, populationâ€based study of post radical prostatectomy urinary incontinence correction surgery. Journal of Surgical Oncology, 2018, 117, 321-327.	1.7	8
32	Concordance of Non–Low-Risk Disease Among Pairs of Brothers With Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1847-1852.	1.6	8
33	SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scandinavian Journal of Urology, 2018, 52, 313-320.	1.0	40
34	Quantity and quality of nucleic acids extracted from archival formalin fixed paraffin embedded prostate biopsies. BMC Medical Research Methodology, 2018, 18, 161.	3.1	16
35	Comparison of 3D printed prostate models with standard radiological information to aid understanding of the precise location of prostate cancer: A construct validation study. PLoS ONE, 2018, 13, e0199477.	2.5	24
36	Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. European Urology, 2017, 72, 345-351.	1.9	16

#	Article	IF	CITATIONS
37	Cannabis Use and Incidence of Testicular Cancer: A 42-Year Follow-up of Swedish Men between 1970 and 2011. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1644-1652.	2.5	48
38	Postoperative mortality 90 days after robotâ€assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide populationâ€based study. BJU International, 2016, 118, 302-306.	2.5	14
39	External validation of models predicting the individual risk of metachronous peritoneal carcinomatosis from colon and rectal cancer. Colorectal Disease, 2016, 18, 378-385.	1.4	24
40	Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. Scandinavian Journal of Urology, 2016, 50, 255-259.	1.0	6
41	Causes of death in men with localized prostate cancer: a nationwide, populationâ€based study. BJU International, 2016, 117, 507-514.	2.5	43
42	Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. Journal of the National Cancer Institute, 2016, 108, djw110.	6.3	69
43	Robotic networks: delivering empowerment through integration. BJU International, 2015, 116, 167-168.	2.5	13
44	Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis. Clinical Genitourinary Cancer, 2015, 13, 280-286.	1.9	21
45	Selective intraoperative cholangiography and risk of bile duct injury during cholecystectomy. British Journal of Surgery, 2015, 102, 952-958.	0.3	70
46	Physical activity and body mass index as predictors of prostate cancer risk. World Journal of Urology, 2015, 33, 1495-1502.	2.2	27
47	Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer. European Urology, 2015, 68, 53-58.	1.9	69
48	Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ, The, 2014, 348, g1502-g1502.	6.0	204
49	Re: Walter Artibani, Vincenzo Ficarra, Ben J. Challacombe, et al. EAU Policy on Live Surgery Events. Eur Urol 2014;66:87–97. European Urology, 2014, 66, e121-e122.	1.9	3
50	Maternal and pregnancy characteristics and risk of infantile hypertrophic pyloric stenosis. Journal of Pediatric Surgery, 2014, 49, 1226-1231.	1.6	42
51	Fathering of Dizygotic Twins and Risk of Prostate Cancer: Nationwide, Population-Based Case-Control Study. PLoS ONE, 2014, 9, e110506.	2.5	2
52	Acquired hypothyroidism as a predictive marker of outcome in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine-kinase inhibitors (TKIs): A literature-based meta-analysis Journal of Clinical Oncology, 2014, 32, 500-500.	1.6	6
53	Acquired hypothyroidism as a predictive marker of outcome in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine-kinase inhibitors (TKIs): A literature-based meta-analysis Journal of Clinical Oncology, 2014, 32, e15567-e15567.	1.6	0
54	Risk of oesophageal adenocarcinoma among individuals born preterm or small for gestational age. European Journal of Cancer, 2013, 49, 2207-2213.	2.8	5

#	Article	IF	CITATIONS
55	Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. International Journal of Epidemiology, 2013, 42, 956-967.	1.9	194
56	Congenital malformations and testicular germ cell tumors. International Journal of Cancer, 2013, 133, 1900-1904.	5.1	60
57	Mortality following hip fractures in men with prostate cancer Journal of Clinical Oncology, 2013, 31, 49-49.	1.6	0
58	Differences in citation rates by country of origin for papers published in top-ranked medical journals: do they reflect inequalities in access to publication?. Journal of Epidemiology and Community Health, 2011, 65, 119-123.	3.7	36
59	Mortality Among Men with Locally Advanced Prostate Cancer Managed with Noncurative Intent: A Nationwide Study in PCBaSe Sweden. European Urology, 2011, 60, 554-563.	1.9	65
60	Subtype-Specific Risk of Testicular Tumors among Immigrants and Their Descendants in Sweden, 1960 to 2007. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1053-1065.	2.5	12
61	Risk of contralateral testicular cancer among men with unilaterally undescended testis: A meta analysis. International Journal of Cancer, 2009, 124, 687-689.	5.1	79
62	Clinical outcome following prostatic capsule- and seminal-sparing cystectomy for bladder cancer in 25 men. Scandinavian Journal of Urology and Nephrology, 2009, 43, 127-132.	1.4	10
63	Does a testicular dysgenesis syndrome exist?. Human Reproduction, 2009, 24, 2053-2060.	0.9	79
64	Similar at a glance, but not the same. International Journal of Cancer, 2008, 123, 1480-1480.	5.1	1
65	Time Trends in Human Fecundability in Sweden. Epidemiology, 2008, 19, 191-196.	2.7	48
66	Gestational Hypertension, Preeclampsia, and Risk of Testicular Cancer. Cancer Research, 2008, 68, 8832-8836.	0.9	16
67	Maternal and Gestational Risk Factors for Hypospadias. Environmental Health Perspectives, 2008, 116, 1071-1076.	6.0	94
68	Age at Surgery for Undescended Testis and Risk of Testicular Cancer. New England Journal of Medicine, 2007, 356, 1835-1841.	27.0	470
69	Maternal smoking and the epidemic of testicular cancerâ€"A nested caseâ€"control study. International Journal of Cancer, 2007, 120, 2044-2046.	5.1	31
70	Genetic and environmental risk factors for testicular cancer. Journal of Developmental and Physical Disabilities, 2007, 30, 230-241.	3.6	79
71	Re: Reduced risk of prostate cancer in men who are childless. International Journal of Cancer, 2006, 118, 788-788.	5.1	0
72	Perinatal Risk Factors for Cancer of the Esophagus and Gastric Cardia: A Nested Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 867-871.	2.5	17

#	Article	IF	CITATION
73	Fecundity and Twinning Rates as Measures of Fertility Before Diagnosis of Germ-Cell Testicular Cancer. Journal of the National Cancer Institute, 2004, 96, 145-147.	6.3	66
74	Perinatal determinants of germ-cell testicular cancer in relation to histological subtypes. British Journal of Cancer, 2002, 87, 545-550.	6.4	58
75	No association between human parvovirus B19 and testicular germ cell cancer. Journal of General Virology, 2002, 83, 2321-2324.	2.9	10
76	Body Size and Testicular Cancer. Journal of the National Cancer Institute, 2000, 92, 1093-1096.	6.3	32
77	Epstein-barr virus and cytomegalovirus in relation to testicular-cancer risk: a nested case-control study. , 1999, 82, 1-5.		31
78	Risk Factor Patterns for Cryptorchidism and Hypospadias. Epidemiology, 1999, 10, 364-369.	2.7	272
79	Risk factor patterns for cryptorchidism and hypospadias. Epidemiology, 1999, 10, 364-9.	2.7	54
80	ARTICLES: Testicular Nonseminoma and Seminoma in Relation to Perinatal Characteristics. Journal of the National Cancer Institute, 1996, 88, 883-889.	6.3	120